
TY  - JOUR
AU  - Sharma, Mukut
AU  - Halligan, Brian D.
AU  - Wakim, Bassam T.
AU  - Savin, Virginia J.
AU  - Cohen, Eric P.
AU  - Moulder, John E.
TI  - The urine proteome as a biomarker of radiation injury
JO  - PROTEOMICS – Clinical Applications
JA  - Prot. Clin. Appl.
VL  - 2
IS  - 7‐8
SN  - 1862-8346
UR  - https://doi.org/10.1002/prca.200780153
DO  - doi:10.1002/prca.200780153
SP  - 1065
EP  - 1086
KW  - Biomarkers
KW  - Nuclear accidents
KW  - Radiation injury
KW  - Radiological terrorism
KW  - Urine proteome
PY  - 2008
AB  - Abstract Terrorist attacks or nuclear accidents could expose large numbers of people to ionizing radiation, and early biomarkers of radiation injury would be critical for triage, treatment, and follow-up of such individuals. However, no such biomarkers have yet been proven to exist. We tested the potential of high throughput proteomics to identify protein biomarkers of radiation injury after total body X-ray irradiation (TBI) in a rat model. Subtle functional changes in the kidney are suggested by increased glomerular permeability for macromolecules measured within 24?h after TBI. Ultrastructural changes in glomerular podocytes included partial loss of the interdigitating organization of foot processes. Analysis of urine by LC-MS/MS and 2-DE showed significant changes in the urine proteome within 24?h after TBI. Tissue kallikrein 1-related peptidase, cysteine proteinase inhibitor cystatin C and oxidized histidine were found to be increased while a number of proteinase inhibitors including kallikrein-binding protein and albumin were found to be decreased postirradiation. Thus, TBI causes immediately detectable changes in renal structure and function and in the urinary protein profile. This suggests that both systemic and renal changes are induced by radiation and it may be possible to identify a set of biomarkers unique to radiation injury.
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Asia-Pacific Journal of Clinical Oncology
JA  - Asia‐Pac J Clin Oncol
VL  - 15
IS  - S9
SN  - 1743-7555
UR  - https://doi.org/10.1111/ajco.13263
DO  - doi:10.1111/ajco.13263
SP  - 104
EP  - 212
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Stroke
VL  - 5
IS  - s2
SN  - 1747-4930
UR  - https://doi.org/10.1111/j.1747-4949.2010.00480.x
DO  - doi:10.1111/j.1747-4949.2010.00480.x
SP  - 1
EP  - 375
PY  - 2010
ER  - 

TY  - JOUR
TI  - Posters
JO  - FEBS Open Bio
JA  - FEBS Open Bio
VL  - 8
IS  - S1
SN  - 2211-5463
UR  - https://doi.org/10.1002/2211-5463.12453
DO  - doi:10.1002/2211-5463.12453
SP  - 105
EP  - 510
PY  - 2018
ER  - 

TY  - JOUR
TI  - POSTER SESSION: BASIC SCIENCE
JO  - European Journal of Heart Failure
JA  - European Journal of Heart Failure
VL  - 12
IS  - S1
SN  - 1388-9842
UR  - https://doi.org/10.1093/eurjhf/hst008
DO  - doi:10.1093/eurjhf/hst008
SP  - S36
EP  - S72
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Fundamental & Clinical Pharmacology
VL  - 26
IS  - s1
SN  - 0767-3981
UR  - https://doi.org/10.1111/j.1472-8206.2012.01032.x
DO  - doi:10.1111/j.1472-8206.2012.01032.x
SP  - 1
EP  - 122
PY  - 2012
ER  - 

TY  - JOUR
TI  - ACR Meeting
JO  - Arthritis & Rheumatism
JA  - Arthritis & Rheumatism
VL  - 64
IS  - S10
SN  - 0004-3591
UR  - https://doi.org/10.1002/art.37735
DO  - doi:10.1002/art.37735
SP  - S1
EP  - S1216
PY  - 2012
AB  - Abstract http://acrmeeting.wiley.com/
ER  - 

TY  - JOUR
TI  - Poster Session Abstracts
JO  - Pediatric Pulmonology
JA  - Pediatr. Pulmonol.
VL  - 46
IS  - S34
SN  - 8755-6863
UR  - https://doi.org/10.1002/ppul.21583
DO  - doi:10.1002/ppul.21583
SP  - 212
EP  - 428
PY  - 2011
ER  - 

TY  - JOUR
TI  - Poster Session
JO  - Pediatric Pulmonology
JA  - Pediatr Pulmonol
VL  - 54
IS  - S2
SN  - 8755-6863
UR  - https://doi.org/10.1002/ppul.22495
DO  - doi:10.1002/ppul.22495
SP  - S155
EP  - S480
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - The Journal of Clinical Hypertension
VL  - 14
IS  - s1
SN  - 1524-6175
UR  - https://doi.org/10.1111/j.1751-7176.2011.00665.x
DO  - doi:10.1111/j.1751-7176.2011.00665.x
SP  - A1
EP  - A144
PY  - 2012
AB  - This supplement can be found at the following link: http://www.ashabstracts.com
ER  - 

TY  - JOUR
TI  - POSTER SESSIONS
JO  - Allergy
VL  - 62
IS  - s83
SN  - 0105-4538
UR  - https://doi.org/10.1111/j.1398-9995.2007.01407.x
DO  - doi:10.1111/j.1398-9995.2007.01407.x
SP  - 167
EP  - 551
PY  - 2007
ER  - 

TY  - JOUR
TI  - Poster Session 2
JO  - International Journal of Gynecological Cancer
VL  - 16
IS  - s3
SN  - 1048-891X
UR  - https://doi.org/10.1111/j.1525-1438.2006.00739.x
DO  - doi:10.1111/j.1525-1438.2006.00739.x
SP  - 695
EP  - 763
PY  - 2006
ER  - 

TY  - JOUR
AU  - Burra, P.
AU  - Senzolo, M.
AU  - Adam, R.
AU  - Delvart, V.
AU  - Karam, V.
AU  - Germani, G.
AU  - Neuberger, J.
AU  - for ELITA and of behalf of ELTR Liver Transplant Centers
TI  - Liver Transplantation for Alcoholic Liver Disease in Europe: A Study from the ELTR (European Liver Transplant Registry)
JO  - American Journal of Transplantation
VL  - 10
IS  - 1
SN  - 1600-6135
UR  - https://doi.org/10.1111/j.1600-6143.2009.02869.x
DO  - doi:10.1111/j.1600-6143.2009.02869.x
SP  - 138
EP  - 148
KW  - Alcohol
KW  - liver cirrhosis
KW  - liver transplantation
KW  - outcome
PY  - 2010
AB  - Alcohol-related liver disease (ALD) is one of the most common indications for liver transplantation (LT). Long-term outcome after LT for ALD versus other etiologies is still under debate. The aim of this study was to compare outcome after LT of patients with ALD, viral (VIR), and cryptogenic cirrhosis. Donor, graft and recipient ELTR variables were analysed in transplants for alcoholic and nonalcoholic cirrhosis (1988?2005) and were correlated with patient survival. Causes of death and/or graft failure were compared between groups. Nine thousand eight hundred eighty ALD, 10 943 VIR, 1478 ALD + VIR and 2410 cryptogenic (CRYP) liver transplants were evaluated. One, 3, 5 and 10 years graft survival rates after LT in ALD patients were 84%, 78%, 73%, 58%, significantly higher than in VIR and CRYP (p = 0.04, p = 0.05). By multivariate analysis, ALD + VIR (RR 1.14) and viral alone (RR 1.06) were significant risk factors for mortality. De novo tumors, cardiovascular and social causes were causes of death/graft failure in higher percentage in ALD groups versus other etiologies. LT for ALD cirrhosis has a favorable outcome, however, hepatitis C virus co-infection seems to eliminate this advantage. Screening for de novo tumors and prevention of cardiovascular complications are essential to provide better long-term results.
ER  - 

TY  - JOUR
TI  - 2006 Abstracts: Twenty-Eighth Annual Meeting of the American Society for Bone and Mineral Research: Pennsylvania Convention Convention Center Philadelphia, Pennsylvania, USA, September 15–19, 2006
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 21
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.5650211409
DO  - doi:10.1002/jbmr.5650211409
SP  - S352
EP  - S401
PY  - 2006
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Journal of Thrombosis and Haemostasis
JA  - Journal of Thrombosis and Haemostasis
VL  - 5
IS  - S2
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2007.tb00020.x
DO  - doi:10.1111/j.1538-7836.2007.tb00020.x
SP  - P-M-501
EP  - P-M-701
PY  - 2007
ER  - 

TY  - JOUR
TI  - P1 – ACNE: ROSACEA
JO  - Journal of the European Academy of Dermatology and Venereology
VL  - 16
IS  - s1
SN  - 0926-9959
UR  - https://doi.org/10.1046/j.1468-3083.16.s1.1.x
DO  - doi:10.1046/j.1468-3083.16.s1.1.x
SP  - 115
EP  - 341
PY  - 2002
ER  - 

TY  - JOUR
TI  - Key Words Index
JO  - Journal of Gastroenterology and Hepatology
JA  - J Gastroenterol Hepatol
VL  - 28
IS  - S3
SN  - 0815-9319
UR  - https://doi.org/10.1111/jgh.12386
DO  - doi:10.1111/jgh.12386
SP  - 956
EP  - 982
PY  - 2013
ER  - 

TY  - JOUR
TI  - Poster Session Abstracts
JO  - Pediatric Pulmonology
JA  - Pediatr. Pulmonol.
VL  - 47
IS  - S35
SN  - 8755-6863
UR  - https://doi.org/10.1002/ppul.22682
DO  - doi:10.1002/ppul.22682
SP  - 223
EP  - 446
PY  - 2012
ER  - 

TY  - JOUR
AU  - Fontana, Robert J.
AU  - Ellerbe, Caitlyn
AU  - Durkalski, Valerie E.
AU  - Rangnekar, Amol
AU  - Reddy, Rajender K.
AU  - Stravitz, Todd
AU  - McGuire, Brendan
AU  - Davern, Timothy
AU  - Reuben, Adrian
AU  - Liou, Iris
AU  - Fix, Oren
AU  - Ganger, Daniel R.
AU  - Chung, Raymond T.
AU  - Schilsky, Mike
AU  - Han, Steven
AU  - Hynan, Linda S.
AU  - Sanders, Corron
AU  - Lee, William M.
AU  - the US Acute Liver Failure Study Group
TI  - Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study
JO  - Liver International
JA  - Liver Int
VL  - 35
IS  - 2
SN  - 1478-3223
UR  - https://doi.org/10.1111/liv.12632
DO  - doi:10.1111/liv.12632
SP  - 370
EP  - 380
KW  - age
KW  - cerebral oedema
KW  - liver transplantation
KW  - prognosis
KW  - regeneration
PY  - 2015
AB  - Abstract Background & Aims The long-term clinical outcomes in initial survivors with acute liver failure (ALF) are not well known. The aim of this study was to provide an overview of the 2-year clinical outcomes among initial survivors and liver transplant (LT) recipients that were alive 3 weeks after enrolment in the Acute Liver Failure Study Group (ALFSG). Methods Outcomes in adult ALFSG patients that were enrolled between 1998 and 2010 were reviewed. Results Two-year patient survival was significantly higher in the 262 LT recipients (92.4%) compared to the 306 acetaminophen (APAP) spontaneous survivors (SS) (89.5%) and 200 non-APAP SS (75.5%) (P < 0.0001). The causes of death were similar in the three groups but the time to death was significantly longer in the LT recipients (P < 0.0001). Independent predictors of 2-year mortality in the APAP group were a high serum phosphate level and patient age (c-statistic = 0.65 (0.54, 0.76)), patient age and days from jaundice to ALF onset in the non-APAP group (c-statistic = 0.69 (0.60, 0.78)), and patient age, days from jaundice, and higher coma grade in the LT recipients (c-statistic = 0.74 (0.61, 0.87)). The LT recipients were significantly more likely to be employed and have a higher educational level (P < 0.05). Conclusions Two-year outcomes in initial survivors of ALF are generally good but non-APAP patients have a significantly lower survival which may relate to pre-existing medical comorbidities. Spontaneous survivors with APAP overdose experience substantial morbidity during follow-up from ongoing psychiatric and substance abuse issues.
ER  - 

TY  - JOUR
TI  - Poster Session Abstracts
JO  - Pediatric Pulmonology
JA  - Pediatr Pulmonol
VL  - 53
IS  - S2
SN  - 8755-6863
UR  - https://doi.org/10.1002/ppul.24152
DO  - doi:10.1002/ppul.24152
SP  - S148
EP  - S456
PY  - 2018
ER  - 
